Aralez Pharmaceuticals Inc (ARZ) Trading Down 5.1%
Aralez Pharmaceuticals Inc (TSE:ARZ) dropped 5.1% during trading on Friday . The stock traded as low as C$1.67 and last traded at C$1.67. Approximately 8,636 shares were traded during trading, a decline of 77% from the average daily volume of 36,800 shares. The stock had previously closed at C$1.76.
The company has a 50 day moving average of $1.66 and a 200-day moving average of $3.28. The firm’s market cap is $111.64 million.
COPYRIGHT VIOLATION WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/17/aralez-pharmaceuticals-inc-arz-trading-down-5-1.html.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization.
Receive News & Stock Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.